Wassil Merrouche

发表

Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations

V. de Lédinghen, P. Couzigou, L. Castéra, 2010, Hepatology.

Transient elastography and biomarkers for liver fibrosis assessment and follow‐up of inactive hepatitis B carriers

V. de Lédinghen, P. Couzigou, B. le Bail, 2011, Alimentary pharmacology & therapeutics.

Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.

V. de Lédinghen, P. Couzigou, F. Roudot-thoraval, 2009, Journal of hepatology.

Liver fibrosis on account of chronic hepatitis C is more severe in HIV‐positive than HIV‐negative patients despite antiretroviral therapy

V. de Lédinghen, V. Soriano, D. Neau, 2008, Journal of viral hepatitis.

Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

V. de Lédinghen, Y. Ngo, M. Rudler, 2014, Journal of hepatology.

Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C

S. Bertrais, F. Oberti, P. Calès, 2014, Hepatology.

Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).

V. de Lédinghen, E. Schiff, Y. Ngo, 2014, Journal of hepatology.

Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease

V. Wong, H. Chan, A. Chan, 2012, The American Journal of Gastroenterology.

Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®.

V. Wong, V. de Lédinghen, H. Chan, 2012, Journal of hepatology.

Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

Julien Vergniol, V. de Lédinghen, P. Couzigou, 2011, Gastroenterology.

Feasibility of liver transient elastography with FibroScan® using a new probe for obese patients

V. de Lédinghen, V. Rigalleau, J. Vergniol, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

Julien Vergniol, V. Wong, V. de Lédinghen, 2010, Hepatology.

Changes of non‐invasive markers and FibroScan values during HCV treatment

P. Couzigou, L. Castéra, J. Vergniol, 2009, Journal of viral hepatitis.

CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis C

P. Couzigou, J. Vergniol, J. Foucher, 2011 .

Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.

V. de Lédinghen, C. Camma', E. Bugianesi, 2019, The American journal of gastroenterology.

Non‐invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography

J. Vergniol, J. Foucher, V. Ledinghen, 2012, Liver international : official journal of the International Association for the Study of the Liver.

FibroScan used in street‐based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study

V. de Lédinghen, J. Foucher, J. Delile, 2009, Journal of viral hepatitis.

Liver stiffness measurement predicts long‐term survival and complications in non‐alcoholic fatty liver disease

V. Wong, G. Wong, J. Foucher, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.

V. Wong, V. de Lédinghen, A. Tuttolomondo, 2017, Journal of hepatology.

Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD

V. Wong, V. de Lédinghen, F. Marra, 2017, Alimentary pharmacology & therapeutics.

Controlled attenuation parameter for the diagnosis of steatosis in non‐alcoholic fatty liver disease

V. Wong, H. Chan, B. le Bail, 2016, Journal of gastroenterology and hepatology.

Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.

V. de Lédinghen, C. Cassinotto, J. Vergniol, 2014, Journal of hepatology.

Liver Stiffness Measurement in Children Using FibroScan: Feasibility Study and Comparison With Fibrotest, Aspartate Transaminase to Platelets Ratio Index, and Liver Biopsy

V. de Lédinghen, L. Sandrin, B. le Bail, 2007, Journal of pediatric gastroenterology and nutrition.

Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy

V. Paradis, P. Bedossa, J. Vergniol, 2017, Digestive Diseases and Sciences.

Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study.

V. de Lédinghen, P. Couzigou, L. Castéra, 2008, Gastroenterologie clinique et biologique.

Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values

V. Wong, V. de Lédinghen, F. Marra, 2017, Hepatology.

Impact of Obesity and ALT Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in NAFLD Patients

V. Wong, A. Chan, E. Bugianesi, 2020 .

989 NEW FIBROSCAN PROBE FOR OBESE PATIENTS. A PILOT STUDY OF FEASIBILITY AND PERFORMANCES IN PATIENTS WITH BMI ≥ 30 kg/m2

V. Rigalleau, L. Sandrin, C. Fournier, 2009 .

New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.

V. de Lédinghen, B. le Bail, C. Bureau, 2019, Journal of hepatology.

Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease

V. Wong, V. de Lédinghen, H. Chan, 2019, Gut.

Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy

Xavier Forns, V. de Lédinghen, X. Forns, 2012, PloS one.

Dynamic and Rapid Changes in Viral Quasispecies by Udps in Chronic Hepatitis C Patients Receiving Telaprevir-Based Therapy

V. de Lédinghen, H. Fleury, M. Kann, 2013, Antiviral therapy.